Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) — ASN Events

Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) (#199)

Hans J Hammers 1 , Elizabeth R Plimack 2 , Jeffrey R Infante 3 , Brian I Rini 4 , David F McDermott 5 , Marc S Ernstoff 6 , Martin H Voss 6 , Padmanee Sharma 7 , Sumanta K Pal 8 , Albiruni Razak 9 , Christian Kollmannsberger 10 , Daniel YC Heng 11 , Jennifer Spratlin 12 , Yun Shen 13 , Paul Gagnier 13 , Asim Amin 14
  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
  2. Fox Chase Cancer Centre, Philadelphia, PA, USA
  3. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA
  4. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
  5. Beth Israel Deaconess Medical Center, Boston, MA, USA
  6. Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
  7. MD Anderson Cancer Center, University of Texas, Houston, TX, USA
  8. City of Hope Comprehensive Cancer Center, Duarte, CA, USA
  9. Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
  10. British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  11. Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
  12. Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
  13. Bristol-Myers Squibb, Princeton, NJ, USA
  14. Levine Cancer Institute, Charlotte, NC, USA
Publish consent withheld
#COSA2015